Recent developments in natural and synthetic drug research for Alzheimer's Disease


Orhan G., Orhan İ. , Sener B.

Letters in Drug Design and Discovery, vol.3, no.4, pp.268-274, 2006 (Journal Indexed in SCI Expanded) identifier identifier

  • Publication Type: Article / Review
  • Volume: 3 Issue: 4
  • Publication Date: 2006
  • Doi Number: 10.2174/157018006776743215
  • Title of Journal : Letters in Drug Design and Discovery
  • Page Numbers: pp.268-274

Abstract

Alzheimer's Disease (AD) is a progressive and degenerative neurological disorder characterized by loss of cognition and memory. However, the pathogenesis of AD is still not clearly known. Current research in drug discovery for treatment of AD involves various targets, being only symptomatic, with the main therapeutic strategies based on "cholinergic hypothesis" and "amyloid cascade hypothesis". During the last decade, inhibitors of acetylcholinesterase (AChE) such as tacrine (Cognex®), donepezil (Aricept®), rivastigmine (Exelon®), and galanthamine (Reminyl®) have been launched. More recently, memantine (Ebixa® ) has been emerged on the market as an N-methyl-D-aspartate (NMDA) receptor antagonist, which has been approved to be effective in the treatment of moderate to severe type of AD. In this review, we will focus on recent status of drug molecules for treatment of AD, currently either that in clinical practice, or still in clinical trials. © 2006 Bentham Science Publishers Ltd.